Analyses and Outlook In spite of opinions to the contrary most investors continue to hold patiently. The Analyses on THRM suggests this is a reasonable strategy, certainly in the near term.
Morningstar's Fair Value sp, which is conservative, is $.47 and their 1-star speculative valuation is $1.17. The resistance and support is converging around $.38 with the greatest level of support at $.375 and the resistance levels at $.385, $.39 and $.395.
From one side of the Pacific (US) to the other (Australia) and in many other countries around the world rapid antigen tests are in high demand and short supply. The niches keep expanding.
With developments continuing between the FDA and Therma Bright there is little to no reason to believe that FDA EUA will not come to fruition. AcuVid is accurate, inexpensive, easy to carry out and the demand continues for just this type of device ...less than 40% of the people on the planet are fully vaccinated.
https://montreal.ctvnews.ca/mcgill-to-offer-rapid-covid-testing-for-students-staff-1.5653214
https://www.medpagetoday.com/special-reports/exclusives/95272
https://www.cbs58.com/news/the-us-races-to-supply-more-at-home-rapid-covid-tests
https://www.smh.com.au/politics/federal/living-with-covid-regular-rapid-testing-and-shorter-quarantine-20211105-p596ee.html
GLTE!!!